The new H2-receptor antagonist, ranitidine, has been compared with cimetidine and metiamide as an inhibitor of gastric acid secretion in the dog. All three compounds were effective both intravenously or by mouth in inhibiting secretion induced by histamine, pentagastrin, or bethanechol. This inhibition was mainly attributable to a reduction in the volume of secretion, although there was also a significant reduction in the concentration of acid secreted. Metiamide was slightly less active than cimetidine, but ranitidine was four to nine times more potent than cimetidine, depending on the secretagogue used. The antisecretory activity of ranitidine does not result from a limitation in blood flow to the gastric mucosa.
It is now well established that the histamine H2-receptor antagonists metiamide and cimetidine inhibit gastric acid secretion in the dog12 and in man.34 Furthermore, cimetidine has proved to be highly effective in the treatment of duodenal ulcer.6 Both metiamide and cimetidine contain an imidazole ring which has been claimed to be an important feature for H2-receptor antagonist activity.6 However, a novel compound, ranitidine (AH 19065) has recently been described7 which lacks an imidazole ring (see Fig. 1 ), but possesses both potent H2-receptor antagonist and gastric antisecretory activity.
The purpose of the present investigation was to compare the new H2-receptor antagonist ranitidine with metiamide and cimetidine as inhibitors of gastric acid secretion in the dog. The effects of the three H2-receptor antagonists have been studied in conscious dogs with Heidenhain pouches during stimulation of gastric acid secretion by three different secretagogues-histamine, pentagastrin and bethanechol.
Methods
Eight male beagles (13-19 kg) with well-established Heidenhain pouches were used, following the method previously described by Daly and Stables.8 Histamine, pentagastrin, or bethanechol was infused intravenously at a dose known to produce a 50% Received for publication 11 December 1979 AH 19065 Ranitidine maximal secretory response in each dog. The doses used were: histamine 0.3-0.5 gkg-'min-1, pentagastrin 1-4 gzg kg-' h,-' and bethanechol 0 5-1-0 ,ug kg-' min.-' Secretion from the Heidenhain pouch drained into a collection vessel which was changed every 15 minutes; the volume of secretion was measured to the nearest 0.1 ml and acid concentration determined by titration against 01 mol/l NaOH to pH7 with a Radiometer TTT2 titration system. Acid output was calculated in tumol H+/min. The secretory stimulant was infused continuously throughout the experiment. Once a plateau of gastric acid secretion had been obtained (less than 15% variation over one hour), a single dose of ranitidine, cimetidine or metiamide was administered as an intravenous bolus or by mouth in a capsule.
The three H2-receptor antagonists were tested against each secretory stimulant over the following range of doses; ranitidine (0-03-1-0 mg/kg), cimetidine (01-3-0 mg/kg), and metiamide (0.3-3 0 mg/kg).
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effects of a range of doses of ranitidine, cimetidine, * and metiamide (Fig. 3) shows that ranitidine is JI i/ clearly the most potent inhibitor of histamine stimulated gastric acid secretion.
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bethanechol. As antagonists, whether given intravenously or by mouth, inhibit secretion stimulated by either pentagastrin or bethanechol. To determine whether the antisecretory effect of ranitidine was the result of a reduction in blood flow through the gastric mucosa was next investigated. In preliminary experiments (Table 2) it was shown that mucosal blood flow slightly decreased after an intravenous dose of ranitidine but the ratio of blood flow to gastric secretion increased markedly, regardless of the secretagogue used. Consequently, the inhibition of gastric secretion by ranitidine does not result from a limitation in blood flow.
While cimetidine was usually slightly more active than metiamide as an antisecretory agent, ranitidine was consistently the most potent of the three H2-receptor antagonists irrespective of the secretagogue used. Table 3 summarises the antisecretory ED50 values for the three antagonists, and gives relative potencies for metiamide and ranitidine in comparison with cimetidine. Metiamide was only 04-0.9 times as active as cimetidine, but ranitidine was 4-9.5 times more active than cimetidine depending on the secretory stimulant employed.
Discussion
Ranitidine is a potent inhibitor of gastric acid secretion in the dog and is qualitatively similar to the established H2-receptor antagonists metiamide and cimetidine. Thus ranitidine is effective in reducing secretion from the Heidenhain pouch of the dog, whether given intravenously or by mouth; and its antisecretory effect is mainly through a reduction in the volume of gastric secretion, with a lesser effect on the concentration of acid secreted. The duration of the antisecretory effect of ranitidine after a single oral dose is as long or longer than that of cimetidine. The antisecretory activity of ranitidine is not due to any limiting action on mucosal blood flow, as the ratio of mucosal blood flow to acid secretion actually rose after administration of ranitidine. Metiamide has also been shown to increase the ratio of mucosal blood flow to acid secretion while reducing acid secretion elicited by either histamine or pentagastrin.10
Ranitidine, when given intravenously or orally to the dog, was always significantly more potent than cimetidine as an inhibitor of gastric acid secretion elicited by histamine, pentagastrin, or the choline ester, bethanechol. The potency of ranitidine relative to cimetidine ranged from 4-3 to 9.5, depending on which secretagogue was used. Cimetidine has been reported to be about twice as active as metiamide as an inhibitor of gastric secretion2, but no direct comparison of their relative potencies in the dog has previously appeared in the literature. In the present study cimetidine was between 1.1 to 2.5 times as active as metiamide, but this difference in potency was not always statistically significant.
In addition to its greater potency, ranitidine also differs from cimetidine in its chemical structure. Ranitidine is a substituted aminomethyl furan, whereas metiamide and cimetidine are both based on the imidazole ring structure of histamine itself. Metiamide was withdrawn from clinical use after there had been a few cases of reversible agranulocytosis."1 This toxic effect is probably associated with the presence of a thiourea group in the metiamide molecule, and does not appear to be a problem with cimetidine, a close structural analogue in which thiourea is replaced by cyanoguanidine.12 A low incidence of minor side-effects has been reported for cimetidine'2 and, if these are unrelated to H2-receptor blockade, they may not occur with a non-imidazole compound like ranitidine.
Initial reports claimed that the H2-receptor antagonists burimamide and metiamide did not antagonise secretion induced by choline esters in the dog.'0 13 However, more recently metiamide and cimetidine have both been described as effective against secretion stimulated by choline esters.2 14 The effectiveness of metiamide as an inhibitor of secretion induced by choline esters in the dog appears to be dependent on the experimental design used.l5 In other systems cimetidine, metiamide, and ranitidine have been shown to be selective antagonists of the effects of histamine at H2-receptors but, in the stomach, these antagonists are effective inhibitors of several gastric secretagogues other than histamine. The reason for this paradox is probably that histamine can increase gastric secretion in two ways-firstly, by a direct stimulant action of its own on the parietal cells and, secondly, by potentiating the stimulant actions of gastrin (or pentagastrin) and acetylcholine (or other similar choline esters).16 17 An H2-receptor antagonist can antagonise both the direct effect of histamine and its potentiating action and thus reduces gastric secretion elicited by histamine, choline esters, or gastrin. Consequently, the effectiveness of ranitidine as an inhibitor of gastric secretion elicited by bethanechol, pentagastrin, or histamine is entirely consistent with its known properties as an H2-receptor antagonist.
Ranitidine, as well as inhibiting gastric acid secretion induced by histamine, pentagastrin, and bethanechol in the dog, will also markedly reduce secretion elicited by 2-deoxy-D-glucose or a test meal. "8 Ranitidine has recently been shown to be a potent inhibitor of pentagastrin stimulated gastric secretion in patients with duodenal ulceration'9 and thus this drug appears to be highly suitable for clinical trial for the treatment of peptic ulceration. 
